NGN-401 gene therapy showed durable, progressive gains in developmental milestones for Rett syndrome patients, with all participants improving and no loss of milestones through 30 months. The therapy remains well-tolerated, and no serious adverse events were reported.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.